• News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • X (Twitter)
  • LinkedIn
Stock Screener·US·Healthcare·BLSM
Share

BlossomHill Therapeutics, Inc. Stocks

$ 13.5Last Updated 06.11.2026

Issuer Rating

2/7
Performance

Modest

Risk

High

Recommendation

Sell

Market Cap

$ 353.05M

$ 13.5
Key Takeaways

Risk factor

Very high price volatility

Data is available to registered users only
Data is available to registered users only

Profitability factor

Favourable analyst view

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

Latest news

17.09.2026 17:40

Newly public biotech BlossomHill rallies on updated trial data for lung cancer drug

09.08.2026 21:00

Robots Backed by DeepSeek Investments and a Wave of Biotech IPOs: Key Takeaways on IPOs Through August 9

07.08.2026 14:59

BlossomHill Therapeutics IPO: Cancer Drug Developer Goes Public

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

No company description

Company Valuation

Greatly overvalued
1/7

Based on key historical and expected multiples, the stock is greatly overvalued relative to its peers.

Data is available to registered users only
Sign up to access detailed valuation

Target Price

Favourable
6/7
Sign up to access analyst forecasts

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

Trending

07.11.2026 19:13

Berkshire has sharply accelerated its share buybacks. Should investors buy these shares?

07.11.2026 17:01

Small-Cap Highlights: Inovio's Surge, Alstom's Plunge, and a Recall of Children's Snacks

07.11.2026 13:01

A Blow to Elon Musk, “Guppy Fry” in the Ocean of AI, Kazakhstan’s Radioactive Armor

07.11.2026 12:01

The Race Between Caesars and Fanatics: What the New Book on the Future of AI Has to Say

07.11.2026 04:32

Burry cut his position in an AI-boom beneficiary by 75%. What other trades did he disclose?

X-channel

Buy

Sell

0 more stocks

Company

  • About
  • Contributors
  • Contacts
  • Legal Information

Social media

  • X (Twitter)
  • LinkedIn

Services

  • Stock Screener
  • Guru Portfolios
  • X (Twitter)
  • LinkedIn
Oninvest© 2026